In Togo, malaria is highly endemic in throughout the country, and is the leading cause of death in children under five with an estimated 1.89 million malaria cases and 3,600 deaths in 2020. Despite the treatment for malaria being relatively low-cost, critical gaps to access and quality of community health systems throughout the country prove challenging to implement effective interventions. We work closely with the Ministry of Health in addressing this through our seasonal malaria chemoprevention (SMC) programme. 

SMC programme 

Malaria Consortium has been a leading implementer of SMC since WHO issued its recommendation to scale up this intervention in 2012. Following the end of the ACCESS-SMC project in 2017, we have continued to support national malaria programmes in Burkina Faso, Chad, Nigeria and Togo to deliver SMC. In 2021, our programme aims to reach more than 20 million children.  We are also conducting research exploring the feasibility, acceptability, and impact of SMC outside of the Sahel in Mozambique and Uganda.  

Find out more

Malaria Consortium in Togo

Bringing extensive experience of SMC delivery since 2014, Togo’s National Malaria Control Programme (PNLP) approached Malaria Consortium in 2019 to explore the possibility of using philanthropic funding to complement funding from the Global Fund and UNICEF to ensure full SMC implementation in the country’s three regions eligible as per the World Health Organization (WHO) recommendations. In 2020, we announced the expansion of our SMC programme to support implementation in Togo to deliver this highly effective intervention to approximately 180,000 eligible children in the Savanes region. 

In addition to supporting with funding to deliver SMC to children in Savanes region, together with the Global Fund and UNICEF we assist with campaign planning, comprehensive training of community distributors and community engagement in the three regions of Savanes, Kara and Centrale. We also undertook an independent end-of-round coverage and quality surveys across all three regions where SMC is implemented to allow the malaria programme and other SMC partners to reliably evaluate the campaign. 

Areas of focus 

Seasonal malaria chemoprevention

Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children under five. 

In 2020, the emergence of COVID-19 required adapting existing protocols for SMC implementation. To minimise the risk of infection and maintain essential malaria services, the 2020 and 2021 (and the currently ongoing) SMC campaigns were implemented using strict infection prevention and control (IPC) measures based on Malaria Consortium and national IPC guidelines. Following implementation, we also undertook a study evaluating the feasibility and acceptability of using the role model approach to improve administration of seasonal malaria chemoprevention drugs in Burkina Faso, Chad and Togo.